Welcome to our dedicated page for Bioadaptives news (Ticker: BDPT), a resource for investors and traders seeking the latest updates and insights on Bioadaptives stock.
Bioadaptives Inc. (BDPT) delivers science-driven nutraceutical innovations through rigorous research and clinical validation. This news hub provides investors and industry observers with essential updates on product developments, research milestones, and strategic initiatives shaping the future of evidence-based wellness solutions.
Access official press releases and curated analysis covering clinical trial progress, intellectual property advancements, and market expansion efforts. Our repository simplifies tracking of regulatory updates, partnership announcements, and scientific breakthroughs in cognitive health, anti-aging formulations, and bioavailability enhancement technologies.
Key updates include R&D investment disclosures, human trial phase completions, and educational outreach programs. Bookmark this page for structured access to material events affecting Bioadaptives' position in the competitive nutraceutical sector, with all content vetted for relevance to long-term company strategy.
BioAdaptives, Inc. (OTCMkts: BDPT) has launched a new line of enhanced nutraceuticals for holistic healthcare practitioners, targeting symptoms associated with COVID-19 aftermath like brain fog and fatigue. The U.S. alternative medicine market is valued at approximately $21 billion, serving over one million healthcare professionals. CEO Dr. Edward Jacobs highlighted the products' neuro-protective, anti-viral, and calming properties. While the current product lineup includes popular items like PluriPain® and PrimiSleep™, new “Nu” branded offerings aim to meet increasing practitioner demand. None of the claims have FDA approval.
BioAdaptives, Inc. (OTCMkts: BDPT) has launched PrimiSleep™, a natural sleep supplement developed to promote relaxation and uninterrupted sleep without cognitive impairment. The product is based on Traditional Chinese Medicine and Ayurvedic principles, addressing the increasing demand for effective sleep solutions, particularly as chronic sleep issues affect over 70 million Americans. The global sleeping aids market is projected to grow from $64 billion in 2021 to $118 billion by 2030, with a CAGR of 7.1%. CEO Edward Jacobs highlights the importance of optimal sleep for overall health.
BioAdaptives, Inc. (OTCMkts: BDPT) has introduced a cost-effective wellness combination package featuring PluriPain®, PrimiLungs™, and PrimiSleep™ to address increased consumer demand for solutions to chronic symptoms. These products may help manage issues like brain fog, pain, and sleep disturbances, particularly in those affected by COVID-19. Each formula is designed to provide specific benefits, and together they are reported to enhance well-being. The introductory package is available for a nominal fee, allowing consumers to experience the synergistic effects firsthand.
BioAdaptives, Inc. (OTCMkts: BDPT) has launched the Canine All-in-One, an advanced daily supplement for dogs, modeled after its successful horse supplement, Equine All-in-One. This product combines the Canine Regen with natural ingredients to address various health issues while reducing the need for multiple supplements. Dog owners report rapid improvements in older dogs’ energy, recovery, and mobility. The global pet supplement market is projected to grow, indicating strong demand for such products. Canine All-in-One is based on eight years of success and safety without adverse effects.
BioAdaptives, Inc. (BDPT) announces a new program aimed at helping seniors afford their advanced nutraceutical supplements amidst rising inflation. The initiative offers discounts for single-container purchases, reducing prices from $59.95-$69.95 to $29.95-$39.95. This strategy is expected to tap into the growing nutraceutical market, projected to reach USD 454.55 billion by 2030, with a CAGR of 9.0%. CEO Edward Jacobs emphasized the importance of making health-related products accessible for seniors, particularly in light of COVID-related health issues and rising living costs.
BioAdaptives, Inc. (OTCMkts: BDPT) announced positive results from a study led by Dr. Lorrin Koran at Stanford Medical School on Pluripain® for Gadolinium Deposition Disease (GDD). The study revealed that 60% of participants experienced significant relief from pain and brain fog. Pluripain® is suggested to reduce opioid dependency in patients. The CEO of BioAdaptives expressed optimism about further studies confirming the supplement's benefits. GDD arises from excessive gadolinium build-up from MRIs, affecting certain patients.
BioAdaptives, Inc. (OTCMkts: BDPT) has acquired U.S. Patent 9,783,432B from inventor Thomas J. Mohr to enhance oxygen capacity in water. This technology embeds oxygen molecules, offering long-term aerobic benefits for performance and health. The company is forming MORO2, Inc. to develop consumer products based on this technology, with marketing set to begin in 2Q 2022. Under the agreement, BioAdaptives holds exclusive rights for two years and has engaged Mohr as a consultant. This acquisition positions the company for growth in nutraceutical-enhanced oxygenated water products.
BioAdaptives, Inc. (OTCMkts: BDPT) has initiated a study of its Lung Armor™ package, which includes the Lung Cleanser™ device and PrimiLungs™ supplement, targeting respiratory health in long-term smokers and those exposed to second-hand smoke. The Lung Cleanser™ is an FDA-cleared medical device aimed at enhancing lung clearance. Research will evaluate user experience and potential improvements in product efficacy, with initial studies planned in the US and possibly Eastern Europe. The company seeks to provide daily support for smokers’ breathing and health through its innovative products.
FAQ
What is the current stock price of Bioadaptives (BDPT)?
What is the market cap of Bioadaptives (BDPT)?
